Arcus Biosciences, Inc. Total Contract Liability
Arcus Biosciences, Inc. (RCUS) had Total Contract Liability of $56.00 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Liabilities
us-gaap:ContractWithCustomerLiability · last filed 2026-08-05
- 2026-06-30: Contract with Customer, Liability $56.00M.
- 2026-03-31: Contract with Customer, Liability $79.00M.
- 2025-12-31: Contract with Customer, Liability $78.00M.
- 2025-09-30: Contract with Customer, Liability $105.00M.
| Period end | Contract with Customer, Liability |
|---|---|
| 2026-06-30 | $56.00M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $79.00M 10-Q · filed 2026-05-05 |
| 2025-12-31 | $78.00M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $105.00M 10-Q · filed 2025-10-28 |
| 2025-06-30 | $131.00M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $291.00M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $319.00M 10-K · filed 2026-02-25 |
| 2024-09-30 | $394.00M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $327.00M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $366.00M 10-Q · filed 2024-05-08 |
| 2024-01-31 | $522.00M 10-K · filed 2026-02-25 |
| 2024-01-29 | $522.00M 10-K · filed 2025-02-25 |
| 2023-12-31 | $398.00M 10-K · filed 2025-02-25 |
| 2023-09-30 | $429.00M 10-Q · filed 2023-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |